EP1261371A4 - Membrane estrogen receptor-directed therapy in breast cancer - Google Patents

Membrane estrogen receptor-directed therapy in breast cancer

Info

Publication number
EP1261371A4
EP1261371A4 EP01912991A EP01912991A EP1261371A4 EP 1261371 A4 EP1261371 A4 EP 1261371A4 EP 01912991 A EP01912991 A EP 01912991A EP 01912991 A EP01912991 A EP 01912991A EP 1261371 A4 EP1261371 A4 EP 1261371A4
Authority
EP
European Patent Office
Prior art keywords
breast cancer
estrogen receptor
directed therapy
membrane estrogen
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01912991A
Other languages
German (de)
French (fr)
Other versions
EP1261371A1 (en
Inventor
Richard J Pietras
Diana C Marquez-Garban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1261371A1 publication Critical patent/EP1261371A1/en
Publication of EP1261371A4 publication Critical patent/EP1261371A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP01912991A 2000-02-25 2001-02-23 Membrane estrogen receptor-directed therapy in breast cancer Withdrawn EP1261371A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18502600P 2000-02-25 2000-02-25
US185026P 2000-02-25
PCT/US2001/005897 WO2001062288A1 (en) 2000-02-25 2001-02-23 Membrane estrogen receptor-directed therapy in breast cancer

Publications (2)

Publication Number Publication Date
EP1261371A1 EP1261371A1 (en) 2002-12-04
EP1261371A4 true EP1261371A4 (en) 2005-04-13

Family

ID=22679250

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01912991A Withdrawn EP1261371A4 (en) 2000-02-25 2001-02-23 Membrane estrogen receptor-directed therapy in breast cancer

Country Status (5)

Country Link
EP (1) EP1261371A4 (en)
JP (1) JP2003523404A (en)
AU (2) AU4171001A (en)
CA (1) CA2400874A1 (en)
WO (1) WO2001062288A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1366366B1 (en) 2000-05-10 2010-10-20 Signe BioPharma Inc. Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
EP1490502B1 (en) * 2001-11-14 2013-01-09 Signe BioPharma Inc. Screening method for predicting susceptibility to breast cancer
EP1499343A4 (en) * 2002-03-28 2005-12-28 Medvet Science Pty Ltd A method of modulating cellular activity
SE0401302D0 (en) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Inhibition of recognized phosphorylation
FR2873699B1 (en) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF
NZ599005A (en) * 2009-08-24 2014-11-28 Phigenix Inc Targeting pax2 for the treatment of breast cancer
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US20220008636A1 (en) * 2020-07-12 2022-01-13 Henry J. Smith Apheresis to remove interfering substances
CN115369092A (en) * 2022-09-30 2022-11-22 北京大学 Quantitative screening method of estrogen receptor antagonist based on cell impedance sensing
CN116284383B (en) * 2023-03-01 2023-11-03 宜兴食品与生物技术研究院有限公司 Method for rapidly obtaining 17 beta-estradiol murine IgG full-length antibody and Fab antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2055441C (en) * 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
US5183736A (en) * 1990-03-30 1993-02-02 La Jolla Cancer Research Foundation Methods using estrogen receptor as a constitutive transcriptional activator and a repressor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABBONDANZA CIRO ET AL: "Characterization and epitope mapping of a new panel of monoclonal antibodies to estradiol receptor", STEROIDS, vol. 58, no. 1, 1993, pages 4 - 12, XP001183746, ISSN: 0039-128X *
KUNISUE H ET AL: "ANTI-HER2 ANTIBODY ENHANCES THE GROWTH INHIBITORY EFFECT OF ANTI-OESTROGEN ON BREAST CANCER CELLS EXPRESSING BOTH OESTROGEN RECEPTORS AND HER2", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 82, no. 1, January 2000 (2000-01-01), pages 46 - 51, XP001008510, ISSN: 0007-0920 *
MOREY ANJALI K ET AL: "Estrogen and progesterone inhibit vascular smooth muscle proliferation", ENDOCRINOLOGY, vol. 138, no. 8, 1997, pages 3330 - 3339, XP002304840, ISSN: 0013-7227 *
See also references of WO0162288A1 *
SOMJEN DALIA ET AL: "Nongenomic effects of an anti-idiotypic antibody as an estrogen mimetic in female human and rat osteoblasts", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 65, no. 1, 1997, pages 53 - 66, XP002304841, ISSN: 0730-2312 *
WITTERS LOIS M ET AL: "Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody", BREAST CANCER RESEARCH AND TREATMENT, vol. 42, no. 1, 1997, pages 1 - 5, XP002304672, ISSN: 0167-6806 *

Also Published As

Publication number Publication date
JP2003523404A (en) 2003-08-05
CA2400874A1 (en) 2001-08-30
AU2001241710B2 (en) 2005-07-21
WO2001062288A1 (en) 2001-08-30
AU4171001A (en) 2001-09-03
EP1261371A1 (en) 2002-12-04

Similar Documents

Publication Publication Date Title
AU2002215907A1 (en) Massaging breast pump and funnel therefor
AU2002212527A1 (en) Thermometry-based breast cancer risk assessment
GB0028429D0 (en) Therapy
IL206604A0 (en) Transmembrane protein expressed in prostate cancer
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU4171001A (en) Membrane estrogen receptor-directed therapy in breast cancer
IL156690A0 (en) Specific human antibodies for selective cancer therapy
AU2890199A (en) Gata-3-expression in human breast carcinoma
GB0005257D0 (en) Breast cancer hormonal therapy
HUP0300339A3 (en) Use of fulvestrant in the treatment of resistant breast cancer
GB0002835D0 (en) Drug resistance in cancer
IL161762A0 (en) Estradiol inhibiting agents in breast cancer
AU2001288921A1 (en) Human breast cancer biomarkers
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
GB0026015D0 (en) Cancer treatment
AU2001257325A1 (en) Cancer treatment
HUP0301833A3 (en) Crf2 ligands in combination therapy
AU2001236782A1 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
AU2001238144A1 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
IL151662A0 (en) Atm mutations in breast cancer
AU2001257168A1 (en) Cancer treatment
AU2001238697A1 (en) Personal breast cancer indicator
GB0017620D0 (en) Flavonoids in cancer treatment
TW417430U (en) Massage divece in brassiere
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/395 A

Ipc: 7C 07K 14/72 B

Ipc: 7A 61K 39/40 B

Ipc: 7A 61K 39/42 B

A4 Supplementary search report drawn up and despatched

Effective date: 20050225

RTI1 Title (correction)

Free format text: MEMBRANE ESTROGEN RECEPTOR-DIRECTED TREATMENT OF CANCER

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070317